| Identification | Back Directory | [Name]
Quinagolide | [CAS]
87056-78-8 | [Synonyms]
D07217
Norprolac
CV-205-502
Quinagolide
Quinagolide (inn/ban)
Quinagolide USP/EP/BP
3-(Diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline
(3S,4aS,10aR)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline | [Molecular Formula]
C20H33N3O3S | [MDL Number]
MFCD07799967 | [MOL File]
87056-78-8.mol | [Molecular Weight]
395.56 |
| Hazard Information | Back Directory | [Uses]
Quinagolide (CV205-502) is a non-ergot dopamine D(2) receptor agonist that promotes dopamine activity. Quinagolide has shown effectiveness in modulating endocrine function, particularly in inhibiting disorders associated with dopamine deficiency. Quinagolide is used to suppress hyperprolactinemia and corresponding clinical symptoms, showing good efficacy. Quinagolide's biological activity enables its use as an important research compound in drug isolation and analysis[1]. | [Definition]
ChEBI: Quinagolide is an organonitrogen heterocyclic compound and an organic heterotricyclic compound. | [Clinical Use]
Hyperprolactinaemia | [Drug interactions]
Potentially hazardous interactions with other drugs
None known | [Metabolism]
Quinagolide is extensively metabolised. Quinagolide
and its N-desethyl analogue are the biologically active
but minor components. Their inactive sulphate or
glucuronide conjugates represent the major circulating
metabolites. Studies performed with 3
H-labelled
quinagolide revealed that more than 95% of the drug is
excreted as metabolites. About equal amounts of total
radioactivity are found in faeces and urine. | [References]
[1] Chiral Separations by Host-Guest Complexation with Cyclodextrin
and Crown Ether in Capillary Zone Electrophoresis |
|
|